Who is sponsoring NCT00918411?

NCT00918411 is sponsored by Astellas Pharma Inc.

What condition does NCT00918411 study?

NCT00918411 studies Irritable Bowel Syndrome.

What drugs are being tested in NCT00918411?

Interventions: Ramosetron, Placebo.

What is the status of NCT00918411?

NCT00918411 is currently COMPLETED.

Last reviewed 2015-10-09 · How we verify

Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

NCT00918411 Phase 4 COMPLETED

The purpose of this study is to explore and examine endpoints that allow evaluation of the "clinically significant improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms" by this drug in patients with diarrhea-predominant irritable bowel syndrome (IBS).

Details

Lead sponsor	Astellas Pharma Inc
Phase	Phase 4
Status	COMPLETED
Enrolment	98
Start date	2009-06
Completion	2009-12

Conditions

Irritable Bowel Syndrome

Interventions

Ramosetron
Placebo

Primary outcomes

IBS severity index (Japanese version) — 12 weeks

Countries

Japan